Bangkok, Thailand — 2025
In a groundbreaking partnership that elevates Thailand’s position in cell-based immunotherapy, Villa Medical Center Phuket (www.thailandstemcell.com) has joined forces with Vega Stem Cell (www.vegastemcell.com) to establish a cutting-edge Natural Killer (NK) cell therapy workflow designed for both research and clinical readiness. This initiative, launched in 2025, represents a significant milestone in the country’s advancement of stem cell therapy, immune cell platforms, and ATMP (Advanced Therapy Medicinal Product) capabilities.
As a subsidiary of Atlantis Bioscience Singapore (www.atlantisbioscience.com), a regional leader in regenerative and immune biologics, Villa Medical Center Phuket brings advanced manufacturing protocols, quality control systems, and reagent innovation to the Thai immunotherapy sector. The collaboration with Vega Stem Cell—Thailand’s premier stem cell treatment provider—establishes a translational platform that links cell research directly to clinical use.
Why NK Cells Are the Future of Immunotherapy
NK (Natural Killer) cells are a type of cytotoxic lymphocyte critical to the body’s innate immune defense. Unlike T-cells, NK cells can rapidly target and destroy virus-infected or cancerous cells without the need for antigen sensitization. This unique property makes NK cell therapy a rapidly growing area of interest in immuno-oncology, autoimmune disease modulation, and infectious disease control.
Globally, NK cells are being investigated and used in:
- CAR-NK therapies for solid tumors and leukemia
- Off-the-shelf NK cell products for immunocompromised patients
- Combination therapies with MSCs (Mesenchymal Stem Cells)
- Stem cell-derived NK products for scalable treatment options
Thailand, with its rising investment in regenerative medicine and health innovation, is poised to become a regional leader in NK cell manufacturing and therapy. The partnership between Villa Medical Center Phuket and Vega Stem Cell provides the infrastructure, knowledge, and regulatory guidance to make this vision a reality.
A Complete NK Cell Workflow: From Isolation to Clinical Application
The NK workflow established under this partnership is designed to be GMP-relevant and scalable, enabling both clinical-grade production and research validation. This makes it suitable for hospitals, academic centers, and biotech developers aiming to incorporate NK cells into ATMP development pipelines.
Key components of the workflow include:
- PBMC or cord blood-based NK cell isolation protocols
- Feeder-free expansion systems using IL-2, IL-15, and proprietary cytokines
- GMP-relevant SOPs for culture, expansion, and cryopreservation
- Flow cytometry panels for purity, viability, and cytotoxicity profiling
- Cryogenic storage solutions for clinical readiness
The platform also supports downstream integration with MSC therapy and exosome production, allowing for multifaceted approaches in personalized and precision medicine.
Vega Stem Cell: Clinical Leadership in Stem Cell Therapy
Vega Stem Cell (www.vegastemcell.com) has built a strong reputation in Thailand and internationally as a centre for excellence in stem cell therapy. Specializing in MSCs derived from umbilical cord tissue, Vega provides patients with personalized regenerative treatment for conditions such as osteoarthritis, neurological disorders, autoimmune diseases, and chronic pain.
With this NK cell collaboration, Vega expands its treatment portfolio to include immune cell-based therapies. Its on-site physicians, laboratory infrastructure, and patient network provide a direct channel for clinical translation of NK research and validation of ATMP-grade workflows.
The partnership allows Vega to:
- Offer compassionate-use NK cell therapy under clinical review
- Collaborate with academic hospitals on joint protocols
- Co-develop immune monitoring and biomarker studies
- Serve as a reference center for Southeast Asian immune therapy
Together, Atlantis and Vega are creating a seamless bridge from cell source to bedside, enabling scalable and scientifically rigorous therapeutic development.
The Role of Atlantis Bioscience Singapore in Regional Expansion
This project is powered by the innovation and regulatory expertise of Atlantis Bioscience Singapore, which supports all Villa Medical Center Phuket projects across Asia. Atlantis Bioscience provides:
- GMP-grade media and reagents for immune cell expansion
- Ready-to-use cytokine cocktails (IL-2, IL-15, IL-21)
- Exosome-compatible serum-free formulations
- Training modules and GMP documentation for audits
- Regional compliance frameworks for ASEAN markets
By extending its R&D capabilities through Villa Medical Center Phuket in Thailand, the company ensures that international best practices in immune therapy manufacturing are upheld throughout the region.
This approach reinforces Atlantis’ vision of building integrated centers of excellence in every country where it operates—focused on safe, effective, and accessible ATMPs and regenerative solutions.
Educational Programs and Clinical Readiness
A major part of this initiative is capacity building. The partnership between Atlantis and Vega includes physician training, researcher workshops, and technical certification programs in:
- NK cell handling and expansion protocols
- GMP documentation and quality control
- Immune profiling using flow cytometry and ELISA
- Clinical case study reviews and treatment planning
These educational programs are targeted at clinicians, researchers, medical technologists, and regulatory specialists who want to understand the use of NK cells in modern therapeutic frameworks.
By 2025, the program will have trained dozens of Thai professionals in NK and ATMP workflows establishing a talent pipeline critical to sustainable industry growth.
Regulatory Support and Clinical Pathways
With guidance from Thailand’s Ministry of Public Health and evolving ATMP regulations, the NK workflow is being developed with full attention to ethical, safety, and legal compliance.
Villa Medical Center Phuket is assisting Vega with:
- Thai FDA filing and clinical trial documentation
- Batch manufacturing records and patient traceability systems
- Import-export licensing for cytokines and culture media
- Data collection standards for NK therapy outcomes
This ensures that all activities fall within national and international frameworks, allowing the project to serve as a model for regulated, responsible use of immune cell therapies in Asia.
Expanding the Clinical Frontier in 2025 and Beyond
The long-term goal of this collaboration is to position Thailand as a regional leader in immunotherapy and ATMP development, with the NK workflow serving as the foundation for future programs including:
- CAR-NK development and licensing
- Exosome-NK hybrid therapies
- MSC-NK co-treatment models for inflammatory conditions
- Oncology-focused immune trials for solid tumors and blood cancers
Villa Medical Center Phuket and Vega Stem Cell aim to integrate with academic partners and international consortia to contribute clinical data and scientific publications, elevating Thailand’s contribution to global immune cell innovation.
Conclusion: A New Era of Immune Cell Therapy in Southeast Asia
With the establishment of a full NK cell workflow in partnership with Vega Stem Cell, Villa Medical Center Phuket has taken a decisive step toward shaping the future of personalized medicine and immune-based stem cell therapy in Thailand. This project highlights the power of collaboration between research institutions, biotech developers, and clinical practitioners.
Backed by the scientific leadership of Atlantis Bioscience Singapore, this initiative aligns with the global momentum toward cell and gene therapy and reinforces Southeast Asia’s role in the advancement of next-generation regenerative medicine.
Villa Medical Center Phuket
Villa Sukhothai, Soi Pasak 8, Choeng Thale,
Thalang District, Phuket, Thailand
Email: atlantisphuket@gmail.com
Phone/WhatsApp: +66 99 301 6969